145 related articles for article (PubMed ID: 38698688)
21. Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy.
Fischer R; Breidert M; Keck T; Makowiec F; Lohrmann C; Harder J
Saudi J Gastroenterol; 2012; 18(2):118-21. PubMed ID: 22421717
[TBL] [Abstract][Full Text] [Related]
22. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy.
Morinaga S; Nakamura Y; Watanabe T; Mikayama H; Tamagawa H; Yamamoto N; Shiozawa M; Akaike M; Ohkawa S; Kameda Y; Miyagi Y
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S558-64. PubMed ID: 21913012
[TBL] [Abstract][Full Text] [Related]
24. Notch1 contributes to chemoresistance to gemcitabine and serves as an unfavorable prognostic indicator in pancreatic cancer.
Du X; Zhao YP; Zhang TP; Zhou L; Chen G; Cui QC; Shi J; Wang TX; You L; Shu H
World J Surg; 2013 Jul; 37(7):1688-94. PubMed ID: 23568245
[TBL] [Abstract][Full Text] [Related]
25. S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.
Okabayashi T; Shima Y; Iwata J; Morita S; Sumiyoshi T; Kozuki A; Tokumaru T; Iiyama T; Kosaki T; Kobayashi M; Hanazaki K
World J Surg; 2014 Nov; 38(11):2986-93. PubMed ID: 25104544
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
Oettle H; Post S; Neuhaus P; Gellert K; Langrehr J; Ridwelski K; Schramm H; Fahlke J; Zuelke C; Burkart C; Gutberlet K; Kettner E; Schmalenberg H; Weigang-Koehler K; Bechstein WO; Niedergethmann M; Schmidt-Wolf I; Roll L; Doerken B; Riess H
JAMA; 2007 Jan; 297(3):267-77. PubMed ID: 17227978
[TBL] [Abstract][Full Text] [Related]
27. DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
Drouillard A; Puleo F; Bachet JB; Ouazzani S; Calomme A; Demetter P; Verset G; Van Laethem JL; Maréchal R
Br J Cancer; 2016 Nov; 115(10):1245-1252. PubMed ID: 27755532
[TBL] [Abstract][Full Text] [Related]
28. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW
Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329
[TBL] [Abstract][Full Text] [Related]
29. Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer.
Merrell KW; Haddock MG; Quevedo JF; Harmsen WS; Kendrick ML; Miller RC; Hallemeier CL
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):561-70. PubMed ID: 26867884
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study.
Inal A; Kos FT; Algin E; Yildiz R; Berk V; Tugba Unek I; Colak D; Colak D; Kucukoner M; Tamer Elkiran E; Helvaci K; Geredeli C; Dane F; Balakan O; Ali Kaplan M; Gok Durnali A; Harputoglu H; Goksel G; Ozdemir N; Buyukberber S; Gumus M; Ozkan M; Benekli M; Isikdogan A;
J BUON; 2012; 17(1):102-5. PubMed ID: 22517701
[TBL] [Abstract][Full Text] [Related]
31. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.
Lee B; Lipton L; Cohen J; Tie J; Javed AA; Li L; Goldstein D; Burge M; Cooray P; Nagrial A; Tebbutt NC; Thomson B; Nikfarjam M; Harris M; Haydon A; Lawrence B; Tai DWM; Simons K; Lennon AM; Wolfgang CL; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Ann Oncol; 2019 Sep; 30(9):1472-1478. PubMed ID: 31250894
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant systemic chemotherapy with gemcitabine for stage IV pancreatic cancer: a preliminary report of initial experience.
Kurosaki I; Hatakeyama K
Chemotherapy; 2005 Oct; 51(6):305-10. PubMed ID: 16224180
[TBL] [Abstract][Full Text] [Related]
33. Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinical review of 1,082 patients.
Kuroda T; Kumagi T; Yokota T; Seike H; Nishiyama M; Imai Y; Inada N; Shibata N; Imamine S; Okada S; Koizumi M; Yamanishi H; Azemoto N; Miyaike J; Tanaka Y; Tatsukawa H; Utsunomiya H; Ohno Y; Miyake T; Hirooka M; Furukawa S; Abe M; Ikeda Y; Matsuura B; Hiasa Y; Onji M;
BMC Gastroenterol; 2013 Aug; 13():134. PubMed ID: 24256464
[TBL] [Abstract][Full Text] [Related]
34. Combining the Glasgow Prognostic Score and Serum Carbohydrate Antigen 19-9 Level Improves the Ability to Predict Early Recurrence in Resected Pancreatic Cancer Patients Receiving Adjuvant Gemcitabine.
Numata K; Morinaga S; Katayama Y; Sawazaki S; Numata M; Godai T; Higuchi A; Shiozawa M; Rino Y; Masuda M; Akaike M
Anticancer Res; 2016 May; 36(5):2467-74. PubMed ID: 27127159
[TBL] [Abstract][Full Text] [Related]
35. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL.
Wang P; Zhuang L; Zhang J; Fan J; Luo J; Chen H; Wang K; Liu L; Chen Z; Meng Z
Mol Oncol; 2013 Jun; 7(3):334-45. PubMed ID: 23177026
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
You DD; Lee HG; Heo JS; Choi SH; Choi DW
J Gastrointest Surg; 2009 Sep; 13(9):1699-706. PubMed ID: 19582512
[TBL] [Abstract][Full Text] [Related]
37. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.
Maréchal R; Mackey JR; Lai R; Demetter P; Peeters M; Polus M; Cass CE; Young J; Salmon I; Devière J; Van Laethem JL
Clin Cancer Res; 2009 Apr; 15(8):2913-9. PubMed ID: 19318496
[TBL] [Abstract][Full Text] [Related]
38. P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment.
Striefler JK; Sinn M; Pelzer U; Jühling A; Wislocka L; Bahra M; Sinn BV; Denkert C; Dörken B; Oettle H; Riess H; Bläker H; Lohneis P
Pathol Res Pract; 2016 Aug; 212(8):726-34. PubMed ID: 27461834
[TBL] [Abstract][Full Text] [Related]
39. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant chemotherapy seems beneficial for invasive intraductal papillary mucinous neoplasms.
Caponi S; Vasile E; Funel N; De Lio N; Campani D; Ginocchi L; Lucchesi M; Caparello C; Lencioni M; Cappelli C; Costa F; Pollina L; Ricci S; Mosca F; Falcone A; Boggi U
Eur J Surg Oncol; 2013 Apr; 39(4):396-403. PubMed ID: 23290583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]